2026-10-30 12:30:02 UTC#545657newconfirmedanalysis
NVO stock news
NVO stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-29 14:12:14 UTC#538120duplicateconfirmednews
Eli Lilly shares rise following previously reported Q3 earnings beat and raised full-year sales forecast
2026-10-29 13:16:00 UTC#537584newconfirmednews
GoodRx partners with Novo Nordisk on employer pricing and joins Lilly Employer Connect as administrator
dow_jonesimportance 0.50trust 0.80GoodRx Holdings, Inc. +0.50Novo Nordisk A/S +0.40Eli Lilly and Company +0.40
2026-10-29 13:15:00 UTC#537599updateconfirmednews
GoodRx details Employer Direct GLP-1 access program with manufacturer pricing from Lilly and Novo Nordisk
tradingviewimportance 0.50trust 0.70GoodRx Holdings, Inc. +0.50Eli Lilly and Company +0.40Novo Nordisk A/S +0.40
2026-10-29 10:50:16 UTC#536416duplicateconfirmednews
Eli Lilly raises FY revenue outlook on weight-loss drug demand, trims profit view due to acquisition charges
reutersimportance 0.60trust 0.90Eli Lilly and Company +0.40Novo Nordisk A/S +0.20AtaiBeckley -0.20+1 entities
2026-10-28 17:28:34 UTC#530960duplicateconfirmednews
Eli Lilly retatrutide trial results show superior weight loss to Novo Nordisk Ozempic, company says
yahooimportance 0.30trust 0.60Eli Lilly and Company +0.60Novo Nordisk A/S -0.50Retatrutide +0.60+1 entities
2026-10-28 14:21:17 UTC#529660duplicateconfirmednews
Eli Lilly's retatrutide shows superior weight loss and blood sugar control vs Novo Nordisk's Ozempic in trial
reutersimportance 0.40trust 0.90Eli Lilly and Company +0.60Novo Nordisk A/S -0.50Retatrutide +0.60+2 entities
2026-10-28 13:03:00 UTC#528988newconfirmedpress release
Novo Nordisk to present new liver data for Wegovy and efruxifermin at AASLD 2026
2026-10-28 11:25:23 UTC#528173duplicateconfirmednews
Eli Lilly's retatrutide shows superior efficacy to Novo Nordisk's Ozempic in Phase 3 trial
seeking alphaimportance 0.30trust 0.70Eli Lilly and Company +0.60Novo Nordisk A/S -0.60Retatrutide +0.60+1 entities
2026-10-28 10:48:01 UTC#527899duplicateconfirmednews
Eli Lilly's retatrutide shows superior weight loss and A1C reduction vs Ozempic in Phase 3 trial
2026-10-28 10:45:00 UTC#527862duplicateconfirmednews
Eli Lilly reports retatrutide Phase 3 TRANSCEND-T2D-2 results showing superior A1C and weight loss vs Ozempic
yahooimportance 0.40trust 0.90Eli Lilly and Company +0.80Novo Nordisk A/S -0.60retatrutide +0.80+1 entities
2026-10-27 20:09:04 UTC#523934newconfirmednews
Novo Resources forms JV with Manhattan Gold for 2,700m RC drilling at Tibooburra project in NSW
financial postimportance 0.30trust 0.70Novo Resources Corp. +0.30Manhattan Gold & Silver +0.30Tibooburra Project +0.30+1 entities
2026-10-27 07:10:42 UTC#519189duplicateconfirmednews
Eli Lilly wins court ruling against Novo Nordisk bid to block weight-loss drug advertising
2026-10-26 22:26:15 UTC#517784duplicateconfirmednews
US judge denies Novo Nordisk injunction against Eli Lilly weight-loss drug advertising
reutersimportance 0.30trust 0.90Eli Lilly and Company +0.40Novo Nordisk A/S -0.40Zepbound +0.20+2 entities
2026-10-26 20:09:13 UTC#516990newconfirmednews
US judge rules in favor of Eli Lilly, allowing continued advertising for weight-loss drugs over Novo Nordisk challenge
2026-10-23 16:12:57 UTC#507855duplicateconfirmednews
Dr. Reddy's launches new generic Ozempic brands to address Obeda supply disruptions
reutersimportance 0.30trust 0.90Dr. Reddy's Laboratories -0.30Novo Nordisk A/S 0Ozempic 0+2 entities
2026-10-23 09:55:18 UTC#505561newconfirmedanalysis
J.P. Morgan projects China, India, Brazil GLP-1 market to reach $22 billion by 2035
reutersimportance 0.50trust 0.80JPMorgan Chase & Co. +0.40Novo Nordisk A/S +0.40Eli Lilly and Company +0.40+2 entities
2026-10-23 09:11:58 UTC#505393newconfirmednews
Weight-loss drug users drive demand for high-protein foods, but face growing skepticism over product quality
reutersimportance 0.40trust 0.80Novo Nordisk A/S +0.20Eli Lilly and Company +0.20Boston Consulting Group 0+2 entities
2026-10-21 06:00:00 UTC#490941newconfirmednews
Galderma, Natura, and L'Oreal target 'Ozempic face' market as obesity drug boom drives demand for facial treatments
reutersimportance 0.40trust 0.80Galderma Group AG +0.30Natura &Co Holding S.A. +0.30L'Oreal S.A. +0.30+2 entities
2026-10-20 12:50:24 UTC#486487duplicateconfirmednews